Nipah Virus Testing Market Share, Size, Trends, Industry Analysis Report, By Sample (Blood, Throat & Nasal Swab, Urine, and Others); By Product Type; By End-User; By Region; Segment Forecast, 2023 - 2032
- Published Date:Jul-2023
- Pages: 114
- Format: PDF
- Report ID: PM3557
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global nipah virus testing market was valued at USD 1,849.24 million in 2022 and is expected to grow at a CAGR of 5.1% during the forecast period. The rapidly growing prevalence of several types of infectious diseases including neurological disorders, hepatitis, AIDS, cancer, and dengue among others along with the growing use of serological testing, which detects antibodies to Nipah virus in the blood and also used to identify the individuals who have been infected with the virus, which are the major factors driving the growth of the market. In addition, with the rising introduction of cost-effective technologies, increasing acceptance of several rapid immunoassay tests, and laboratory automation coupled with the continuous improvements in diagnosis-seeking rates across the world, are likely to have positive impact on the market.
To Understand More About this Research: Request a Free Sample Report
For instance, in December 2022, ICMR-NIV, announced that they have developed a new and highly sensitive test kit, which could detect the Nipah virus-specific antibodies. The new kit will be very critical to outbreak investigations and also surveillance activities and will be used by experts to detect the active cases.
Moreover, the rapidly growing incorporation of artificial intelligence and machine learning algorithms across the globe in the recent years, have been mainly developed to help analyze and interpret Nipah virus testing data. As these tools can easily assist in identifying patterns and trends in the data, predicting the likelihood of an outbreak, and informing public health interventions, which has gained significant traction and being widely adopted by large healthcare companies worldwide.
The outbreak of the COVID-19 pandemic has significantly impacted the growth of the nipah virus testing market. The rapid spread of the deadly coronavirus across the globe has disrupted supply chains globally, and also affected the availability and distribution of testing kits and related products for nipah virus, that has led to delays in testing and an overall decrease in demand for testing services.
For Specific Research Requirements, Speak to Research Analyst
Industry Dynamics
Growth Drivers
The rising consumer awareness regarding the potential of this virus to cause various kinds of illness, that forced companies to develop more advanced & innovated diagnostic technologies like PCR and ELISA with enhanced and improved accuracy and speed of NiV infection testing, are the factors influencing the market growth. Additionally, increased number of companies investing heavily in R&D development of testing technologies and method, that helps in making the early diagnosis critical, is also contributing positively towards the nipah virus testing market growth.
Furthermore, the rapid emergence and popularity of next-generation sequencing (NGS), which is a high-throughput technique that can sequence large amounts of DNA or RNA quickly and accurately and is mainly used to sequence the entire genome of nipah virus, which has led to a better understanding of the virus and its transmission, are also driving the demand and growth of the global market over the years.
Report Segmentation
The market is primarily segmented based on sample, product type, end-user, and region.
|
By Sample |
By Product Type |
By End-User |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
Blood segment held the significant market share in 2022
The blood segment held the significant market share in terms of revenue in 2022 with a healthy growth rate, mainly attributable to growing prevalence for these sample type, as they are reliable and effective method for the diagnosis of nipah virus infection, as it enables the detection of specific antibodies or viral RNA in the blood and provide accurate diagnosis, which is very crucial for effective management and treatment of the infection. Advancements in technology that have led to the development of new and improved blood sample-based testing methods including nucleic acid tests and immunoassays, which offer higher sensitivity and specificity, thereby propelling the segment growth.
The throat & nasal swap segment is likely to grow at fastest growth rate over the coming years, on account of growing proliferation for nasal & throat samples, due to its several characteristics like easy to collect, minimally invasive, and less painful compared to other sample types such as blood or cerebrospinal fluid, which makes them a more attractive option for patients and healthcare providers also.
ELISA kits segment accounted for the largest market share in 2022
The ELISA kits segment accounted for highest global market share in 2022, and is likely to retain its market position throughout the projected period, which is mainly driven by its high throughput and unmatched reliability to monitor and manage diseases markers along with this, ability to allow the quantitative measurements for soluble antigens that are found in human body serum or even in body fluids. The increasing healthcare expenditure globally has resulted in the development and adoption of advanced diagnostic tests for various diseases and also led to the increased demand for ELISA kits across the globe at rapid pace.
The RT-PCR based kits segment is expected to exhibit highest growth rate during the study period, that is mainly attributable to constant rise in the demand for fast and accurate diagnosis of the infection and surge in the popularity of these kits due to their short time and better accuracy compared to other kits available in the market.
Hospitals segment dominated the global market in 2022
Hospitals garnered substantial share in 2022, mainly due to easy availability of advanced testing facilities in the hospitals and increased number of government initiatives providing financial relief to patients opting for several types of surgeries. The growing healthcare infrastructure across several countries, that has led to an increase in the number of hospitals and healthcare facilities and also increased the accessibility of nipah virus testing services, driving the demand and growth of the market.
The diagnostic centers segment is likely to gain substantial growth rate over the coming years, on account of increased number of diagnostic centers that are well-equipped with advanced testing services and have access to the state-of-the-art equipment and experienced personnel across both developed and developing economies.
Asia Pacific region is expected to witness highest growth over the forecast period
The Asia Pacific region is anticipated to be the fastest growing region with a healthy CAGR during the projected period, which is highly accelerated to rapid increase in the healthcare spending, leading to greater investment in disease & diagnosis treatment along with the surging focus of several governments towards the development of healthcare system to combat the growing number of outbreaks of nipah virus. Additionally, the increasing availability of advanced diagnostic technologies such as PCR and ELISA, which has made it easier to detect the nipah virus, has been fostering the regional market growth.
The North America region led the industry market with considerable share in 2022, owing to the robust presence of well-established and developed healthcare infrastructure and increased number of people becoming more and more aware regarding the threat of this virus, coupled with the growing focus of research authorities on understanding the transmission, pathogenesis, and treatment of nipah virus.
Competitive Insight
Some of the major players operating in the global market include Lupin, Starlake Bioscience, MyBioSource, Krishgen Biosystems, Roche Diagnostics, Aurobindo, Novartis, Bio-Rad Laboratories, Xaretto, Liferiver, Merck, Vivacure, Minapharm, Creative Diagnostics, Luminex Corporation, Quidel Corporation, Roche, Abbexa, GenMark Diagnostics, Seegene, and Hologic.
Recent Developments
- In July 2022, National Institute of Allergy & Infectious Diseases, started new clinical trial, which will evaluate the investigational vaccine for preventing infection with the Nipah virus. This experimental vaccine is manufactured by Moderna, and was developed in the collaboration with the NIAID’s research facility.
- In September 2021, Kerala, announced the inauguration of a new Nipah testing lab at the Kozhikode Medical College, and the lab has been set up in coordination with NIV Pune and their Alappuzha centre. The new lab will coduct RT-PCR tests and point of care testing mainly for the Nipah virus
Nipah Virus Testing Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 1,940.78 million |
|
Revenue forecast in 2032 |
USD 3,036.68 million |
|
CAGR |
5.1% from 2023 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019 – 2021 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
|
Segments covered |
By Sample, By Product Type, By End-User, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Lupin Ltd., Starlake Bioscience, MyBioSource, Krishgen Biosystems, Roche Diagnostics, Aurobindo, Novartis AG, Bio-Rad Laboratories Inc., Xaretto, Liferiver, Merck KGaA, Vivacure, Minapharm, Creative Diagnostics, Luminex Corporation, Quidel Corporation, F. Hoffmann-La Roche Ltd., Abbexa Ltd., GenMark Diagnostics Inc., Seegene Inc., and Hologic Inc. |
FAQ's
key companies in nipah virus testing market are Lupin, Starlake Bioscience, MyBioSource, Krishgen Biosystems, Roche Diagnostics, Aurobindo, Novartis.
The global nipah virus testing market is expected to grow at a CAGR of 5.1% during the forecast period.
The nipah virus testing market report covering key segments are sample, product type, end-user, and region.
key driving factors in nipah virus testing market are growing incorporation of artificial intelligence and machine learning algorithms
The global nipah virus testing market size is expected to reach USD 3,036.68 million by 2032.
